Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials - 02/12/19
, Lisa Wruck, PhD a, Michael J. Pencina, PhD a, Robert M. Clare, MS a, Renato D. Lopes, MD, PhD a, John H. Alexander, MD a, Sean O'Brien, PhD a, Mitchell Krucoff, MD a, Sunil V. Rao, MD a, Tracy Y. Wang, MD, MHS, MSc a, Lesley H. Curtis, PhD a, L. Kristin Newby, MD a, Christopher B. Granger, MD a, Manesh Patel, MD a, Kenneth Mahaffey, MD b, Joseph S. Ross, MD, MHS c, Sharon-Lise Normand, PhD d, Benjamin C. Eloff, PhD e, Daniel A. Caños, PhD f, Yuliya V. Lokhnygina, PhD a, Matthew T. Roe, MD, MHS a, Robert M. Califf, MD a, Danica Marinac-Dabic, MD, PhD e, Eric D. Peterson, MD, MPH aAbstract |
Background |
Medicare insurance claims may provide an efficient means to ascertain follow-up of older participants in clinical research. We sought to determine the accuracy and completeness of claims- versus site-based follow-up with clinical event committee (+CEC) adjudication of cardiovascular outcomes.
Methods |
We performed a retrospective study using linked Medicare and Duke Database of Clinical Trials data. Medicare claims were linked to clinical data from 7 randomized cardiovascular clinical trials. Of 52,476 trial participants, linking resulted in 5,839 (of 10,497 linkage-eligible) Medicare-linked trial participants with fee-for-service A and B coverage. Death, myocardial infarction (MI), stroke, and revascularization incidences were compared using Medicare inpatient claims only, site-reported events (+CEC) only, or a combination of the 2. Randomized treatment effects were compared as a function of whether claims-based, site-based (+CEC), or a combined system was used for event detection.
Results |
Among the 5,839 study participants, the annual event rates were similar between claims- and site-based (+CEC) follow-up: death (overall rate 5.2% vs 5.2%; adjusted κ 0.99), MI (2.2% vs 2.3%; adjusted κ 0.96), stroke (0.7% vs 0.7%; adjusted κ 0.99), and any revascularization (7.4% vs 7.9%; adjusted κ 0.95). Of events detected by claims yet not reported by CEC, a minority were reported by sites but negatively adjudicated by CEC (39% of MIs and 18% of strokes). Differences in individual case concordance led to higher event rates when claims- and site-based (+CEC) systems were combined. Randomized treatment effects were similar among the 3 approaches for each outcome of interest.
Conclusions |
Claims- versus site-based (+CEC) follow-up identified similar overall cardiovascular event rates despite meaningful differences in the events detected. Randomized treatment effects were similar using the 2 methods, suggesting claims data could be used to support clinical research leveraging routinely collected data. This approach may lead to more effective evidence generation, synthesis, and appraisal of medical products and inform the strategic approaches toward the National Evaluation System for Health Technology.
Le texte complet de cet article est disponible en PDF.Plan
Vol 218
P. 110-122 - décembre 2019 Retour au numéro
Article précédent
- Associations between ?-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease
- Jay S. Shavadia, Yinggan Zheng, Jennifer B. Green, Paul W. Armstrong, Cynthia M. Westerhout, Darren K. McGuire, Jan H. Cornel, Rury R. Holman, Eric D. Peterson
- Safety and effectiveness of dabigatran at 2 years: Final outcomes from Phase II of the GLORIA-AF registry program
- Micha? Mazurek, Christine Teutsch, Hans-Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Chang-Sheng Ma, Kenneth J. Rothman, Miney Paquette, Kristina Zint, Lionel Riou França, Shihai Lu, Dorothee B. Bartels, Menno V. Huisman, Gregory Y.H. Lip, on behalf of the GLORIA-AF Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?